BRL Medicine

Based in Shanghai, China, and founded in 2013, BRL Medicine operates as a biotechnology company that focuses on providing gene editing, cell therapy, and related services. The company was recognized as the National High-tech Enterprise. It has a 7000-square-meter GMP pilot plant and an operating team of nearly 200 people. The company has a branch office in Beijing.

In December 2022, its gene therapy cured six cases of severe thalassemia. The founder and chairman of the board, Mingyao Liu, has served as the Dean of Life Sciences for 8 years. In November 2024, BRL Medicine raised a series B+ funding for approximately CNY 200 million. The company mainly provides gene therapy services.

It uses gene editing and other technologies to develop therapies for the treatment of genetic diseases, malignant tumors, autoimmune diseases, etc. The company has built technology platforms including gene editing technology innovation platforms, hematopoietic stem cell platforms, non-viral fixed-point integration CAR-T platforms, etc. Products include non-viral site-specific integration of PD1-CAR-T cells targeting CD19, UCAR-T for B-cell malignant tumor diseases, etc. The company generates revenue by providing gene therapy platforms and related services.

The company will advance the clinical transformation and marketing of pipeline products, as well as the global research and development of product pipelines.